Avoid common mistakes on your manuscript.
Retraction to: Inflammation (2014) 37(1):154–162
DOI: 10.1007/s10753-013-9724-x
This article has been retracted at the request of the Editor-in-Chief.
The authors have published results from exactly the same clinical study and patient population in 6 separate articles, without referencing the publications in any of the later articles:
1. Derosa, G., Cicero, A.F.G., Carbone, A., Querci, F., Fogari, E., D’angelo, A., Maffioli, P. 2013. Olmesartan/amlodipine combination versus olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients. Clinical and Experimental Hypertension 35: 301–307. doi:10.3109/10641963.2012.721841.
2. Derosa, G., Cicero, A.F.G., Carbone, A., Querci, F., Fogari, E., D’Angelo, A., Maffioli, P. 2013. Effects of an olmesartan/amlodipine fixed dose on blood pressure control, some adipocytokines and interleukins levels compared with olmesartan or amlodipine monotherapies. Journal of Clinical Pharmacy and Therapeutics 38: 48–55. doi:10.1111/jcpt.12021.
3. Derosa, G., Cicero, A.F.G., Carbone, A., Querci, F., Fogari, E., D’Angelo, A., Maffioli, P. 2013. Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies. Journal of the American Society of Hypertension 7: 32–39. doi:10.1016/j.jash.2012.11.006.
4. Derosa, G., Cicero, A.F.G., Carbone, A., Querci, F., Fogari, E., D’Angelo, A., Maffioli, P. 2013. Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies. Expert Opinion on Drug Safety 12: 621–629. doi:10.1517/14740338.2013.816674.
5. Derosa, G., Cicero, A.F.G., Carbone, A., Querci, F., Fogari, E., D’Angelo, A., Maffioli, P. 2014. Different aspects of sartan + calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients. Inflammation 37: 154–162. doi:10.1007/s10753-013-9724-x.
6. Derosa, G., Cicero, A.F.G., Carbone, A., Querci, F., Fogari, E., D’Angelo, A., Maffioli, P. 2014. Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation. European Journal of Pharmaceutical Sciences 51: 26–33. doi:10.1016/j.ejps.2013.08.031.
In addition, the article in Inflammation contains results published especially in articles 2 and 6, which is the main reason for retraction of the article in Inflammation.
The publisher apologizes for the inconvenience caused.
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found at doi: http://dx.doi.org/10.1007/s10753-013-9724-x.
About this article
Cite this article
Derosa, G., Cicero, A.F.G., Carbone, A. et al. Retraction Note to: Different Aspects of Sartan + Calcium Antagonist Association Compared to the Single Therapy on Inflammation and Metabolic Parameters in Hypertensive Patients. Inflammation 39, 502 (2016). https://doi.org/10.1007/s10753-015-0223-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10753-015-0223-0